AzaSite Plus

**AzaSite Plus** is an investigational ophthalmic combination drug developed by InSite Vision and later owned by Sun Pharmaceutical for inflammatory eyelid and ocular surface diseases including blepharitis and blepharoconjunctivitis. It combines **azithromycin 1%** with **dexamethasone 0.1%** in InSite Vision's **DuraSite** mucoadhesive ocular delivery system. The intended rationale is dual-action treatment: azithromycin provides antibacterial activity and anti-inflammatory effects relevant to lid margin disease, while dexamethasone is a corticosteroid that suppresses ocular inflammation. Public clinical-trial and publication records identify AzaSite Plus as **ISV-502**, a late-stage ophthalmic candidate studied in Phase 3 settings for blepharoconjunctivitis and blepharitis, but the provided public evidence does not show marketing approval.

Brand names

AzaSite Plus

Other names

azithromycin + dexamethasoneazithromycin 1% + dexamethasone 0.1%azithromycin-dexamethasone